BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual MeetingPRNewsWire • 09/11/20
BioMarin Pharmaceutical (BMRN) Gains As Market Dips: What You Should KnowZacks Investment Research • 09/04/20
BioMarin (BMRN) Down 34.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/03/20
BioMarin Declining Factor Levels Unlikely To Impact Uniqure Or Sangamo Phase 3 Hemophilia TrialsSeeking Alpha • 08/26/20
Regenerative Medicine: Does BioMarin Complete Response Letter Change The Outlook?Seeking Alpha • 08/25/20
Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite DirectionsThe Motley Fool • 08/19/20
BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drugMarket Watch • 08/19/20
BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock PlungesInvestors Business Daily • 08/19/20
BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia APRNewsWire • 08/19/20